secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0000879169-23-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q1: Jakafi rev $580M (+7%); Opzelura $57M (+343%); raises Jakafi FY guidance to $2.55-2.63B
--------------------------------------------------------------------------------

- Total net product revenues $693M (+14% YoY); total GAAP revenues $808.7M (+10% YoY).
- GAAP net income $21.7M ($0.10 diluted EPS) vs $38.0M ($0.17) in Q1 2022; Non-GAAP net income $84.6M ($0.37).
- Jakafi FY 2023 guidance raised: bottom end to $2.55B from $2.53B; new range $2.55-$2.63B.
- FDA issued complete response letter for ruxolitinib XR (once-daily) in MF, PV, GVHD; next steps unclear.
- Discontinued parsaclisib combo trials in MF (LIMBER-304/313) and development in wAIHA; axatilimab Phase 2 cGVHD data on track for mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/0000879169-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/incy-20230502.htm
  HTML page:      https://secwatch.observer/filing/0000879169-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer